Compare Chubb Ltd (CB) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chubb Ltd vs Recursion Pharmaceuticals Inc — how do they compare? Chubb Ltd trades at $344.57 (market cap $137.59B), while Recursion Pharmaceuticals Inc trades at $3.38 (market cap $1.75B). The key difference: Chubb Ltd is far larger — about 78.6× Recursion Pharmaceuticals Inc's market cap, and Chubb Ltd pays a 1.15% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CB | RXRX | |
|---|---|---|
Market Cap | $137.59B | $1.75B |
Sector | Financials | Health |
52-Week High | $361.17 | $6.79 |
52-Week Low | $265.99 | $2.84 |
Enterprise Value | $158.64B | $1.17B |
Dividend Yield | 1.15% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chubb Ltd
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination makes the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
Read more on CB →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
